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Taxanes and platinum derivatives 
impair Schwann cells via distinct 
mechanisms
Satoshi Imai1, Madoka Koyanagi1, Ziauddin Azimi2,3, Yui Nakazato1, Mayuna Matsumoto1, 
Takashi Ogihara1, Atsushi Yonezawa1, Tomohiro Omura1, Shunsaku Nakagawa1, Shuji 
Wakatsuki4, Toshiyuki Araki4, Shuji Kaneko  2, Takayuki Nakagawa1 & Kazuo Matsubara1
Impairment of peripheral neurons by anti-cancer agents, including taxanes and platinum derivatives, 
has been considered to be a major cause of chemotherapy-induced peripheral neuropathy (CIPN), 
however, the precise underlying mechanisms are not fully understood. Here, we examined the direct 
effects of anti-cancer agents on Schwann cells. Exposure of primary cultured rat Schwann cells to 
paclitaxel (0.01 μM), cisplatin (1 μM), or oxaliplatin (3 μM) for 48 h induced cytotoxicity and reduced 
myelin basic protein expression at concentrations lower than those required to induce neurotoxicity 
in cultured rat dorsal root ganglion (DRG) neurons. Similarly, these anti-cancer drugs disrupted myelin 
formation in Schwann cell/DRG neuron co-cultures without affecting nerve axons. Cisplatin and 
oxaliplatin, but not paclitaxel, caused mitochondrial dysfunction in cultured Schwann cells. By contrast, 
paclitaxel led to dedifferentiation of Schwann cells into an immature state, characterized by increased 
expression of p75 and galectin-3. Consistent with in vitro findings, repeated injection of paclitaxel 
increased expression of p75 and galectin-3 in Schwann cells within the mouse sciatic nerve. These 
results suggest that taxanes and platinum derivatives impair Schwan cells by inducing dedifferentiation 
and mitochondrial dysfunction, respectively, which may be important in the development of CIPN in 
conjunction with their direct impairment in peripheral neurons.
Taxanes and platinum derivatives are effective first-line chemotherapy agents. However, up to 50% of patients 
receiving these anti-cancer agents develop a dose-limiting side effect: chemotherapy-induced peripheral neu-
ropathy (CIPN). Symptoms include paresthesia, dysesthesia, numbness, loss of balance, and muscle weakness1–3. 
To date, there is no effective way of preventing and/or treating CIPN, which can become chronic and persist for 
months or years after termination of chemotherapy4, 5.
Several animal models of CIPN have been developed to examine the causal mechanisms. Early morphological 
studies have provided evidence that paclitaxel induces distal axonopathy after systemic administration at rela-
tively high doses or after local injection directly into a peripheral nerve6, 7. Based on these results, taxane-induced 
peripheral neuropathy has been believed to be secondary to taxane-induced inhibition of the dynamic assembly 
and disassembly of β-tubulin, resulting in a progressive distal axonopathy8–11. However, growing evidence sug-
gests an alternative hypothesis7, 12–14. For example, electron microscopic studies of rat peripheral nerves show that 
treatment with low dose paclitaxel causes a painful peripheral neuropathy, but fails to induce axonal degeneration 
in peripheral nerves. On the other hand, platinum derivatives such as cisplatin and oxaliplatin exert cytotoxic 
effects in the dorsal root ganglia (DRG) neurons, which are mediated via formation of inter- and intra-strand 
crosslinks in DNA, and accumulation of platinum-mitochondrial DNA adducts15, 16. However, it is suggested that 
the impairment of satellite cells and Schwann cells or glial activation in the spinal cord, as well as DRG sensory 
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neurons, are also involved in the pathogenesis of platinum derivative-induced neuropathy17. Thus, the complex 
machinery underlying CIPN pathogenesis remains unclear and is the subject of much debate.
Schwann cells are peripheral nervous system glial cells that form a thin myelin sheet by tightly wrapping 
around axons to enable rapid saltatory conduction of action potentials18, 19. A growing body of evidence suggests 
that Schwann cells play a crucial role in the outgrowth and guidance of regrowing peripheral axons after injury. 
Immediately after peripheral nerve injury, Schwann cells in the injured area transdifferentiate and migrate to the 
distal end to form a denervated Schwann cell band20, 21. The growth cone of a regrowing peripheral nerve fiber 
advances toward its original target using the Schwann cells as a guide. Thus, Schwann cells play a major support-
ive role in the maintenance of the peripheral nervous system, raising the intriguing possibility that impairment of 
Schwann cells and consequent disruption of intercellular interactions between myelin-forming mature Schwann 
cells and axons by anti-cancer agents may be important for the pathogenesis of CIPN. Based on this hypothesis, 
the present study was designed to ascertain the direct effect of anti-cancer agents (paclitaxel, cisplatin and oxalip-
latin) on primary Schwann cell cultures and on myelin-forming Schwann cells in the mouse sciatic nerve.
We show for the first time that treatment with paclitaxel induces the dedifferentiation of myelin-forming 
Schwann cells, whereas cisplatin and oxaliplatin induced cytotoxicity accompanied by mitochondrial dysfunction 
at concentrations lower than those required to impairment of DRG neurons. The present data suggest that these 
direct effects of paclitaxel, cisplatin and oxaliplatin on Schwann cells (as well as a their direct toxicity in peripheral 
neurons) might be the underlying cause of CIPN.
Results
Differentiation of cultured rat immature Schwann cells. We utilized cultured primary Schwann cells 
from the sciatic nerves of neonatal rats to evaluate the direct effect of anti-cancer agents. After 2 days of culture in 
differentiation medium, Schwann cells showed a differentiated cell phenotype, characterized by increased expres-
sion of pro-myelinating transcription factor Oct6 protein, myelinating regulator transcription factor Krox20 pro-
tein and mRNA (Figs 1a and b, Supplementary Figs S1 and S2), and the major myelin proteins MBP protein 
and mRNA (Fig. 1b,c and Supplementary Fig. S2). Before cell differentiation, there was little or no expression 
of these Schwann cell markers. Consistent with previous reports showing that Sox10 is a marker constitutively 
expressed throughout Schwann cell differentiation22, 23, we observed expression of Sox10 protein and mRNA on 
both immature and differentiated Schwann cells (Fig. 1a,b, Supplementary Figs S1 and S2). We further confirmed 
sufficient induction of Schwann cell differentiation by noting almost complete disappearance of both immuno-
reactivity (IR) and mRNA expression of an immature Schwann cell marker, p75 neurotrophin receptor (Fig. 1b,c 
and Supplementary Fig. S2).
Anti-cancer agents reduce the viability of cultured Schwann cells. We next evaluated the effects of 
anti-cancer agents on the viability of differentiated Schwann cells using a 3-(4,5-dimethyldiazol-2-yl)-2,5-diph
enyltetrazolium bromide (MTT) assay. Each of the anti-cancer agents reduced the viability of Schwann cells in a 
concentration-dependent manner after either 24 or 48 h of treatment (Fig. 2). The number of viable cells detected 
Figure 1. Differentiation of primary cultured Schwann cells obtained from the sciatic nerves of neonatal 
rat pups. (a) A representative Western blot showing specific lineage markers (Oct6, Krox20, and Sox10) in 
Schwann cells just before (left lane) and 2 days after (right lane) differentiation. Actin is shown as an internal 
control. (b) Representative RT-PCR showing expression of MBP, Krox20, SOX10 and p75 mRNA in Schwann 
cells just before (left lane) and 2 days after (right lane) differentiation. GAPDH is shown as an internal control. 
Full images of Western blot (a) and RT-PCR (b) are shown in Supplementary Figs S1 and S2, respectively. (c) 
Immunofluorescent staining for MBP (upper) and p75 (lower) in Schwann cells just before (left) and 2 days 
after (right) differentiation. Scale bar: 100 μm. A mature cell phenotype is characterized by induced expression 
of MBP, Oct6 and Krox20, and loss of p75 expression. All experiments were conducted using at least three 
independent samples.
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following 24 h exposure to paclitaxel, cisplatin or oxaliplatin (0.03, 3 or 3 μM, respectively) was significantly lower 
than after exposure to vehicle (Fig. 2a–c). Paclitaxel, cisplatin and oxaliplatin (0.01, 1 and 3 μM, respectively) 
showed significant cytotoxic effects against Schwann cells after 48 h (Fig. 2d–f). Treatment for 48 h tended to be 
more toxic than treatment for 24 h. Thus, 0.01 μM paclitaxel, 1 μM cisplatin and 3 μM oxaliplatin were taken to be 
the minimum concentrations showing a significant effect against Schwann cells.
Paclitaxel, but not cisplatin and oxaliplatin, induces morphological changes in cultured 
Schwann cells. To gain further insight into the direct effects of anti-cancer agents on Schwann cells, we 
examined the effects of paclitaxel, cisplatin and oxaliplatin on the morphology of differentiated Schwann cells 
(Fig. 3a). Differentiated cells had a typical Schwann cell phenotype, being bipolar and spindle shaped, with a small 
cytoplasm. Cells also stained positive for MBP. Treatment with paclitaxel (0.01 μM), cisplatin (1 μM) or oxalip-
latin (3 μM) for 48 h reduced the number of MBP-positive Schwann cells. Expression of MBP was significantly 
lower after treatment with paclitaxel (0.001 and 0.01 μM) or cisplatin (1 and 3 μM) in a concentration-dependent 
manner (Fig. 3b and Supplementary Fig. S3). Unlike cisplatin and oxaliplatin, paclitaxel caused marked morpho-
logical changes, characterized by retraction of bipolar processes and a rounded shape (Fig. 3a).
Anti-cancer agents induce impairment of myelin formation in a mixed culture of Schwann 
cells and DRG neurons. The direct effects of anti-cancer agents on the viability and morphology of rat 
primary DRG neurons were also investigated (Fig. 4a). Primary DRG neurons stained with an antibody specific 
for the neuronal marker microtubule-associated protein-2 (MAP2) were spherical, with multi-neuritic processes. 
Treatment with paclitaxel (0.01 μM), cisplatin (1 μM) or oxaliplatin (3 μM) for 48 h did not affect the viability or 
morphology of primary DRG neurons. By contrast, exposure to the three drugs at higher concentrations (pacl-
itaxel, 0.1 μM; cisplatin, 3 μM; and oxaliplatin, 10 μM) reduced the number of neurons and their dendritic trees, 
and shortened the length of the neuritic processes, when compared with vehicle treatment.
The next study was undertaken to determine whether treating Schwann cell/DRG neuron co-cultures with 
anti-cancer agents leads to demyelination. In a mixed culture of Schwann cells and DRG neurons, Schwann cells 
differentiated along the DRG axons and eventually formed MBP-positive myelin segments, as indicated by the 
apparent overlap of MAP2- and MBP-IR (Supplementary Fig. S4). Treatment with paclitaxel (0.01 μM), cisplatin 
(1 μM) or oxaliplatin (3 μM) for 48 h led to a significant reduction in MBP-IR, suggesting loss of myelinating 
Schwann cells in the co-cultures. However, treatment did not affect MAP2-positive neural axons and MAP2-IR 
(Fig. 4b and c).
Cisplatin and oxaliplatin, but not paclitaxel, cause mitochondrial dysfunction in cultured 
Schwann cells. Cisplatin directly binds to both mitochondrial DNA and nuclear DNA, thereby inducing dys-
function, vacuolization, and degradation of mitochondria in DRG neurons24. To determine whether anti-cancer 
agents induce mitochondrial dysfunction in cultured Schwann cells, we performed fluorescence microscopic 
analyses using the Δψm-sensitive probe MitoTracker Red (Fig. 5). This probe used for mitochondria labeling 
Figure 2. Viability of Schwann cells after exposure to paclitaxel, cisplatin or oxaliplatin. At 2 days after culture in 
differentiation medium, Schwann cells were treated with vehicle (0.1% DMSO), paclitaxel (a,d; 0.001–0.1 μM), 
cisplatin (b,e; 0.1–10 μM) or oxaliplatin (c,f; 0.1–10 μM) for 24 h (a–c) or 48 h (d–f). Cell viability was measured 
in an MTT assay, and the results were expressed as a percentage relative to vehicle-treated cells. Each column 
represents the mean ± S.E.M. n = 3–6. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. the vehicle-treated group.
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is a derivative of X-Rosamine, which fluoresces upon oxidation, passively diffuses across the plasma membrane 
due its lipophilic nature and accumulates in functional mitochondria driven by Δψm25. Images shown in Fig. 5a 
(merged image shown for the vehicle-treated group) indicate that mitochondria are preferentially confined at the 
perinuclear region of Schwann cells. Treatment with paclitaxel (0.01 μM) for 48 h (the same concentration that 
caused marked morphological changes in Schwann cells) had no effect on the intensity of immunofluorescent 
labeling of mitochondria. By contrast, the number of stained mitochondria was markedly reduced after expo-
sure to cisplatin (1 μM) or oxaliplatin (3 μM) for 48 h. The total number of mitochondria-labeled cells per 100 
4,6-diamidino-2-phenylindole (DAPI)-positive cells observed after treatment with either cisplatin or oxaliplatin 
for 48 h was significantly lower than that observed in the vehicle control group, whereas there was no difference 
between the vehicle- and paclitaxel-treated groups (Fig. 5b). We could not detect any changes in the morphology 
and the number of DAPI-stained mitochondria in cisplatin- or oxaliplatin-treated Schwann cells. The decreased 
fluorescence of Mitotracker in Schwann cells after the treatment with platinum derivatives may be due to the loss 
of membrane potential, rather than mitochondrial degradation.
Taxanes induces dedifferentiation of cultured Schwann cells. To better understand the direct effect 
of paclitaxel on Schwann cells, we focused on the expression pattern of p75 and galectin-3, markers of immature 
and dedifferentiated Schwann cell, respectively. Fluorescence microscopic analyses revealed only weak p75-IR 
but robust glial fibrillary acidic protein (GFAP)-IR (a typical Schwann cell marker) in Schwann cells following a 
48 h exposure to cisplatin (1 μM) or oxaliplatin (3 μM), a pattern similar to that observed in the vehicle-treated 
group. By contrast, treatment with paclitaxel (0.01 μM) for 48 h led to a significant increase in p75-IR in 
GFAP-immunopositive Schwann cells when compared with that in the vehicle-, cisplatin- or oxaliplatin-treated 
group (Fig. 6a and b). Expression of p75 mRNA was also significantly higher in the paclitaxel-treated group than 
in the vehicle-treated group, whereas cisplatin (1 µM) had no effect (Fig. 6c). Similarly, galectin-3-IR and mRNA 
expression was significantly increased in Schwann cells treated with paclitaxel (0.01 μM) for 48 h, whereas cispla-
tin (1 μM) had no effect (Fig. 7). To evaluate the relationship between the inhibition of the dynamic assembly/
disassembly of β-tubulin by paclitaxel and Schwann cell dedifferentiation, we examined the effects of docetaxel 
(another taxane derivatives) or vincristine (an inhibitor of tubulin assembly) on Schwann cells. Like paclitaxel, 
treatment with docetaxel (0.001–0.1 μM) or vincristine (0.001–0.1 μM) for 48 h reduced Schwann cell viabil-
ity in a concentration-dependent manner. Under these conditions, both docetaxel (0.01 μM) and vincristine 
(0.01 μM) induced an increase in p75- and galectine-3-IR in Schwann cells, a pattern similar to that observed in 
the paclitaxel-treated group (Supplementary Fig. S5).
Paclitaxel causes Schwann cell dedifferentiation in the mouse sciatic nerves. When mice were 
repeatedly treated intraperitoneal (i.p.) with paclitaxel (4 mg/kg × 4), the 50% paw withdrawal threshold in 
response to tactile stimuli decreased gradually at 4 and 7 days after the first injection (Supplementary Fig. S6). 
Under these conditions, p75-IR in sciatic nerves of mice treated with paclitaxel was also examined (Fig. 8a). 
Figure 3. Effects of paclitaxel, cisplatin and oxaliplatin on Schwann cell morphology and MBP expression. (a) 
Phase (upper) and fluorescence (lower) micrographs of differentiated Schwann cells labeled with an anti-MBP 
antibody. Differentiated Schwann cells were treated with vehicle (0.1% DMSO), paclitaxel (0.01 μM), cisplatin 
(1 μM) or oxaliplatin (3 μM) for 48 h. Cisplatin and oxaliplatin reduced the number of MBP-positive Schwann 
cells, but did not affect cell morphology. Unlike cisplatin and oxaliplatin, paclitaxel induced morphological 
changes, characterized by retraction of bipolar processes and a rounded shape. Scale bar: 100 μm (25 μm in 
enlarged images). (b) Expression of MBP in Schwann cells 48 h after treatment with vehicle (0.1% DMSO), 
paclitaxel (0.001 and 0.01 μM) or cisplatin (1 and 3 μM) was analyzed by Western blotting. (Upper panels) 
Representative Western blot showing expression of MBP and actin. (Lower panels) Quantification of band 
intensity. The intensity of each band was normalized to that of actin (loading control). Each column represents 
the mean ± S.E.M. n = 5–8. *p < 0.05 and ***p < 0.001 vs. the vehicle-treated group. Images of the full blots are 
shown in Supplementary Fig. S3.
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Figure 4. Effects of paclitaxel, cisplatin and oxaliplatin on primary cultured DRG neurons or on co-cultures 
of Schwann cells and DRG neurons. (a) Immunofluorescence staining of primary cultured DRG neurons for 
MAP2. Primary cultured DRG neurons were treated with vehicle (0.1% DMSO), paclitaxel (0.01 and 0.1 μM), 
cisplatin (1 and 3 μM) or oxaliplatin (3 and 10 μM) for 48 h. Only higher doses of paclitaxel (0.1 μM), cisplatin 
(3 μM) and oxaliplatin (10 μM) reduced the number of DRG neurons and associated dendritic trees, and 
shortened the neuritic processes. Scale bar: 100 μm. (b) Co-cultures were treated with vehicle (0.1% DMSO), 
paclitaxel (0.01 μM), cisplatin (1 μM), or oxaliplatin (3 μM) for 48 h. Scale bar: 200 μm. Each treatment reduced 
formation of MBP-positive myelin; however, no morphological changes were observed in MAP2-positive DRG 
neurons. (c) MBP- or MAP2-IR in co-cultures. Each column represents the mean ± S.E.M. n = 3. ***p < 0.001 
vs. the vehicle-treated group.
www.nature.com/scientificreports/
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Repeated injection of paclitaxel increased p75-IR in the longitudinal section of the sciatic nerve, although only 
weak p75-IR was detected in the same section from saline-treated mice. The p75-immunolabeling pattern 
appeared to surround MAP2-positive neural axons, and was localized in GFAP-positive Schwann cells. Consistent 
with this, galectin-3-IR in longitudinal sections of sciatic nerve from paclitaxel-treated mice also increased. 
Galectin-3-IR in the sciatic nerve of paclitaxel-treated mice was highly co-localized in GFAP-positive Schwann 
cells, whereas only weak galectin-3-IR was detected in the sciatic nerve of saline-treated mice. Quantitative analy-
sis revealed that p75- and galectin-3-IR in the sciatic nerve of paclitaxel-treated mice was significantly higher than 
that in saline-treated mice, however, there was no difference in MAP2-IR between paclitaxel- and saline-treated 
mice (Fig. 8b).
Discussion
Here, we showed for the first time that paclitaxel induced dedifferentiation of myelin-forming Schwann cells 
with their morphological changes, whereas both cisplatin and oxaliplatin induced cell toxicities in Schwann 
cells accompanied with mitochondrial dysfunction at concentrations lower than those required to induce 
neurotoxicity.
Schwann cell precursors, which represent the first transitional stage of the Schwann cell lineage, differentiate 
into immature Schwann cells, which then give rise to pro-myelinating Schwann cells. These cells eventually develop 
into mature myelin-forming Schwann cells26. Schwann cells express specific lineage markers at each stage of dif-
ferentiation27. Consistent with previous studies, we found that Schwann cells dissociated from the sciatic nerve 
showed an immature phenotype, with low expression of a myelin-associated molecule (MBP) and myelinating 
transcription factors (Oct6 and Krox20), and high expression of p7518, 28. We also observed accelerated transforma-
tion of Schwann cells into differentiated Schwann cells when cultured in differentiation medium, characterized by 
almost complete disappearance of p75 expression and increased expression of MBP, Oct6 and Krox2029, 30.
We showed that in vitro treatment with paclitaxel, cisplatin or oxaliplatin at clinically relevant plasma con-
centrations31–33 had clear and direct effects on primary cultured Schwann cells. Previous reports suggest that 
mitochondrial dysfunction and subsequent oxidative stress in peripheral neurons are essential mechanisms 
underlying platinum derivative-induced CIPN34. However, the present results indicate that cisplatin and oxalipla-
tin have direct cytotoxic effects on Schwann cells without inducing morphological changes, and that these effects 
are accompanied by mitochondrial dysfunction at drug concentrations lower than those required to induce neu-
rotoxicity. Like platinum derivatives, in vitro treatment with paclitaxel induced direct cytotoxic effects against 
Schwann cells, but caused dynamic morphological changes without any mitochondrial dysfunction in Schwann 
cells at relatively lower concentration (0.01 μM). By contrast, a previous report shows that in vitro treatment 
with paclitaxel causes mitochondrial dysfunction in both cultured neurons and Schwann cells35. In that report, 
a higher concentration of paclitaxel (approximately 0.29 μM) was applied to neural and Schwann cell cultures, 
whereas we used paclitaxel at 0.01 μM (the minimum concentrations showing a significant effect against Schwann 
cells) to minimize its cytotoxic effects. Thus, it seems likely that lower concentrations of paclitaxel can induce 
morphological changes in Schwann cells prior to mitochondrial dysfunction.
Figure 5. Changes in mitochondrial activity in Schwann cells after treatment with paclitaxel, cisplatin or 
oxaliplatin. (a) Fluorescence micrographs of Schwann cells labeled with the MitoTracker probe (red) and 
DAPI (blue). Schwann cells were treated with vehicle (0.1% DMSO), paclitaxel (0.01 μM), cisplatin (1 μM) 
or oxaliplatin (3 μM) for 48 h. Scale bar: 50 μm (10 μm in enlarged images) in the vehicle-treated group. (b) 
Number of mitochondria-labeled cells per 100 DAPI-positive cells. The intensity and number of fluorescently 
labeled mitochondria were reduced after treatment with either cisplatin or oxaliplatin, but not after treatment 
with paclitaxel. Each column represents the mean ± S.E.M. n = 12. *p < 0.05 and **p < 0.01 vs. the vehicle-
treated group.
www.nature.com/scientificreports/
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It should be noted that the treatment with relatively low concentrations of paclitaxel, cisplatin and oxaliplatin 
reduced myelin-forming Schwann cells in the Schwann cell/DRG neuron co-cultures without causing damages 
to the neurons. Furthermore, repeated treatment with paclitaxel had no meaningful effect on the MAP2-positive 
axons of sciatic nerves from mice with mechanical allodynia. Thus, the present findings provide evidence that 
Schwann cells might be a candidate target of these anti-cancer agents that induce CIPN. However, previous 
light and electron microscopy studies demonstrate that no severe demyelination of peripheral nerve axons 
occurs in rats after the weekly i.p. injection of cisplatin or paclitaxel for 4–5 weeks36, 37. It is widely accepted that 
myelin-forming Schwann cells participate in the maintenance and repair of peripheral nerves via direct cell-cell 
interaction with axons or via release of neurotrophins18, 19, 21. A reduction of myelin-forming Schwann cells causes 
neurological dysfunction or abnormal neural conduction, both of which may underlie the pathogenesis of dia-
betic neuropathy38 and Charcot-Marie-Tooth disease39. Taken together, the present findings suggest that platinum 
derivatives- or paclitaxel-induced impairment of myelin-forming Schwann cells with mitochondrial dysfunction 
or dynamic morphological changes, respectively, seem likely to result in the myelin instability and reduction in 
myelin sheath integrity. Analysis of nerve action potential recordings in rodents suggested that multiple injection 
of paclitaxel reduces the peak amplitude and conductance velocity40, 41. In addition, the reduction of the peak 
amplitude is observed in humans treated with paclitaxel42. Reduced nerve conductance velocity is also docu-
mented in rats treated with oxaliplatin43. It is possible that functional impairment of peripheral neurons may be 
due to myelin instability and a reduction of myelin sheath integrity induced by the anti-cancer agents.
Figure 6. Effect of paclitaxel, cisplatin and oxaliplatin on expression of p75 in primary cultured Schwann cells. 
Schwann cells were treated with vehicle (0.1% DMSO), paclitaxel (0.01 μM), cisplatin (1 μM) or oxaliplatin 
(3 μM) for 48 h. (a) Immunofluorescent staining of primary cultured Schwann cells for p75 (red) and GFAP 
(green). Scale bar: 100 μm. (b) p75-IR in Schwann cells. Each column represents the mean ± S.E.M. n = 3. 
***p < 0.001 vs. the vehicle-treated group. Only weak p75-IR was observed in GFAP-positive Schwann cells 
after treatment with vehicle, cisplatin, or oxaliplatin, whereas paclitaxel increased p75-IR in GFAP-positive 
Schwann cells. (c) Quantitative real-time PCR analysis of p75 mRNA expression in Schwann cells. Each 
column represents the mean ± S.E.M. n = 3. ***p < 0.001. Treatment with paclitaxel, but not cisplatin, led to a 
significantly increased in expression of p75 mRNA.
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On the other hand, Peters et al. report that expression of a stress-inducible gene, ATF3, in rat DRG neurons 
increases at 4 to 10 days after intravenous administration of paclitaxel, whereas ATF3 expression in Schwann 
cells is not observed until Day 6 post-infusion, suggesting that paclitaxel preferentially affects DRG neurons44. 
The results presented herein show that lower concentrations of anti-cancer agents directly affect Schwann cells, 
although we never clarified its temporal and functional effects on DRG neurons. Thus, our present data do not 
exclude the possibility that preferential impairment of peripheral neurons by the anti-cancer agents is responsible 
for CIPN. Nevertheless, the present data suggest that the direct effects of anti-cancer agents on Schwann cells 
might contribute to the pathogenesis of CIPN in conjunction with their direct impairment of peripheral neurons. 
Further experiments will be needed to validate the current in vitro findings by using animal models of CIPN fol-
lowing repeated administration of anti-cancer agents, just like clinical treatment protocols.
The key finding of this study is that treatment with paclitaxel, but not platinum derivatives, causes dedif-
ferentiation of Schwann cells, as indicated by increased expression of an immature Schwann cell marker, p75, 
increased expression of a dedifferentiated Schwann cell marker, galectin-3 (also known as macrophage-2 anti-
gen), and reduced expression of a differentiated Schwann cell marker, MBP. We also showed increased expression 
of p75 and galectin-3 in Schwann cells surrounding the neural axon in sciatic nerves isolated from mice with 
paclitaxel-induced peripheral neuropathy. Myelinating Schwann cells can transform into an immature phenotype 
Figure 7. Effect of paclitaxel, cisplatin and oxaliplatin on expression of galectin-3 in primary cultured 
Schwann cells. Schwann cells were treated with vehicle (0.1% DMSO), paclitaxel (0.01 μM) or cisplatin (1 μM) 
for 48 h. (a) Immunofluorescence staining of primary cultured Schwann cells with DAPI (blue) and an anti-
galectin-3 antibody (green). Scale bar: 100 μm. (b) Galectin-3-IR in Schwann cells. Each column represents 
the mean ± S.E.M. n = 3. ***p < 0.001 vs. the vehicle-treated group. Only weak galectin-3-IR was observed 
in Schwann cells after treatment with vehicle or cisplatin, whereas paclitaxel increased galectin-3-IR in 
Schwann cells. (c) Quantitative real-time PCR analysis of galectin-3 mRNA expression in Schwann cells. Each 
column represents the mean ± S.E.M. n = 3. ***p < 0.001. Treatment with paclitaxel, but not cisplatin, led to a 
significant increase in expression of galectin-3 mRNA.
www.nature.com/scientificreports/
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and re-enter the cell cycle to support nerve regeneration in response to peripheral nerve injury45. p75 is induced 
in demyelinating Schwann cells during Wallerian degeneration and regrowth of peripheral axons, and is involved 
in Schwann cell dedifferentiation46–48. Dedifferentiated Schwann cells also show high expression of galectin-3, 
which is not detectable in immature Schwann cells and plays an important role in lectin-mediated phagocytosis 
of degraded material at the site of injury49, 50. Thus, to the best of our knowledge, the present data are the first to 
suggest that paclitaxel induces Schwann cells to dedifferentiate into an immature state, which is akin to Schwann 
cell transformation after the nerve injury. Recently, Nobusue et al. proposed a new mechanism to explain the 
relationship between cytoskeletal dynamics and cellular differentiation of adipocytes51. They suggest that depo-
lymerization of actin fibers in adipocytes triggers the differentiation program, which is mediated by increased 
expression of a transcriptional regulator of adipogenesis. Of particular note is that, similar to paclitaxel, docetaxel 
and vincristine, which prevents microtubule assembly, facilitated transformation of Schwann cells into an imma-
ture state, characterized by increased expression of p75 and galectin-3. These results support the idea that taxanes 
(including paclitaxel)-mediated inhibition of cytoskeletal dynamics may induce dedifferentiation of Schwann 
cells, although further studies are needed to identify the underlying molecular mechanisms. The present findings 
allow us to consider that a unique phenomenon, such as paclitaxel-induced dedifferentiation of Schwann cells, is 
likely responsible for the disruption of cross talk between myelin-forming Schwann cells and axons, resulting in 
induction of CIPN after paclitaxel treatment.
In conclusion, the data presented herein suggest that cisplatin and oxaliplatin are directly cytotoxic to Schwann 
cells accompanied with mitochondrial dysfunction. By contrast, we show for the first time that paclitaxel causes 
dedifferentiation of Schwann cells. These phenomena may disrupt cross talk between myelin-forming mature 
Schwann cells and axons, thereby promoting peripheral neuropathy induced by the anti-cancer agents.
Figure 8. Changes in the expression of p75 and galectin-3 in sciatic nerves isolated from mice treated with 
paclitaxel. Paclitaxel (4 mg/kg) was injected intraperitoneally on Days 0, 3, 5, and 7. At 1 day after the last 
injection, mice were fixed and subjected to immunohistochemical assay. (a) Longitudinal sections of sciatic 
nerve isolated from saline- or paclitaxel-treated mice were co-immunolabeled for p75 (red), or MAP2, 
GFAP or galectin-3 (green). Scale bar: 50 μm (10 μm in enlarged images). Repeated injection of paclitaxel 
increased p75-IR in GFAP- or galectin-3-positive Schwann cells surrounding MAP2-positive neural axons. (b) 
Quantification of the intensity of fluorescence associated with MAP2, p75 or galectin-3. Each column represents 
the mean ± S.E.M. n = 3–5. *p < 0.05 and **p < 0.01 vs. the vehicle-treated group.
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Materials and Methods
Drugs and chemicals. Cisplatin (LKT Laboratories, Inc., St Paul, MN, USA) and oxaliplatin (Wako Pure 
Chemical Industries, Osaka, Japan) were dissolved in phosphate-buffered saline (PBS, pH 7.4) at a concentration 
of 1 mM and distilled water at a concentration of 10 mM, respectively, prior to use. Paclitaxel (Sigma-Aldrich, St. 
Louis, MO, USA; 100 μM) was prepared in dimethyl sulfoxide (DMSO, Nacalai Tesque, Kyoto, Japan) and stored 
at −80 °C. Each drug solution was diluted in the appropriate culture medium to achieve the desired concentration 
before use.
Animals. All experiments were performed according to the ethical guidelines of the Kyoto University Animal 
Research Committee. The protocol was approved by the Kyoto University Animal Research Committee (per-
mission number: 2014–45, 2015–38, Med Kyo 15140 and Med Kyo 16067). All efforts were made to minimize 
the number of animals used and limit experimentation to only what was necessary. Pregnant Wistar/ST rats, 
male Wistar/ST rats (6–8 weeks old) and male C57BL/6 J mice (7–8 weeks old) were purchased from Japan SLC 
(Shizuoka, Japan). All animals were housed under a 12 h light-dark cycle at a constant ambient temperature 
(24 °C ± 1 °C) and humidity (55% ± 10%) and allowed access to food and water ad libitum. Schwann cells were 
prepared from the sciatic nerves of neonatal rats (1–4 days old).
Culture of Schwann cells from the sciatic nerves of neonatal rats. Rat pups (post-natal day 1–4) 
were sacrificed by cervical dislocation, and the sciatic nerve was dissected quickly under sterile conditions. 
Following removal of the epineurium, the nerves were washed twice in ice-cold PBS and transferred to 24 well 
plates (Greiner Holding AG, Kremsmünster, Austria) containing 1 ml of culture medium (serum-free Advanced 
DMEM/F-12; Thermo Fisher Scientific, Waltham, MA, USA, supplemented with 0.292 mg/ml L-glutamine and 
1% penicillin-streptomycin) containing 250 U/ml hyaluronidase type I-S (Sigma-Aldrich) and 160 U/ml colla-
genase type I (Sigma-Aldrich). After 2 h of incubation at 37 °C, tissue fragments were dissociated by trituration 
through 1 ml micropipette tips and the suspension was centrifuged at 300 × g for 5 min at room temperature. 
After re-suspension in maintenance medium (culture medium containing 2 μM forskolin (Sigma-Aldrich) dis-
solved in DMSO and supplemented with 20 ng/ml heregulin β-1 (Sigma-Aldrich) dissolved in 5% trehalose 
(Nacalai Tesque)), the cells were cultured on poly-L-lysine (PLL; Sigma-Aldrich)-coated 75 cm2 culture flasks. 
After 2 days of culture, Schwann cells were purified by magnetic activated cell separation with a monoclonal anti-
body against p75 neurotrophin receptor (Merck Millipore Co., Darmstadt, Germany), according to the manufac-
turer’s instructions (Miltenyi Biotec., Bergisch Gladbach, Germany). The cells were then cultured in PLL-coated 
100 mm culture dishes containing Advanced DMEM/F-12 medium supplemented with 10% heat inactivated fetal 
bovine serum (FBS, Sigma-Aldrich), 1% penicillin-streptomycin, 0.292 mg/ml L-glutamine, 2 μM forskolin, and 
10 ng/ml heregulin β-1. After 2 days, the cells were detached and incubated on ice with a mouse anti-CD90/Thy1 
antibody (1:1000, Abcam, Cambridge, UK) diluted in serum-free culture medium containing 3% bovine serum 
albumin (BSA) to remove contaminating fibroblasts. After 2 h of culture, the suspension was centrifuged and the 
cells were incubated for an additional 1 h at 37 °C in rabbit complement-HLA-ABC (Thermo Fisher Scientific, 
Inc.) diluted 1:4 in serum-free culture medium containing 3% BSA. The suspension was centrifuged at 300 × g 
for 5 min, and the cells were washed twice with culture medium. The purified immature Schwann cells were 
then cultured under standard conditions (in maintenance medium) on tissue culture dishes or 10 mm coverslips 
(Matsunami Glass, Osaka, Japan) pre-coated with 0.1 mg/ml PLL. Cells were stained with DAPI, and the ratio of 
cells showing specific immunostaining for a Schwann cell phenotypic marker (S100β) or Thy-1 (contaminated 
cells) versus the total number of DAPI-positive cells was evaluated. The purity of the Schwann cells (based on 
S100β-immunolabeling) was initially 96%, but increased to 99.6% after purification.
Schwann cell differentiation. At 4–7 days post-cell purification, the maintenance medium was removed 
and the cells were detached using 0.05% Trypsin-EDTA (Nacalai Tesque, Inc.). After detachment, the trypsin 
was deactivated by addition of medium supplemented with 10% FBS. To obtain differentiated Schwann cells, 
cells were cultured for 2 days in differentiation medium (serum-free Advanced DMEM/F-12 containing 1% 
penicillin-streptomycin, 0.292 mg/ml L-glutamine, 20 μM forskolin, and 20 ng/ml heregulin β-1) in 6 or 48 well 
plates or on coverslips pre-coated with 0.1 mg/ml PLL and 0.5 μg/ml laminin (Thermo Fisher Scientific, Inc.). 
Cells were exposed to anti-cancer agents 2 days after plating and culture in differentiation medium.
Primary culture of DRG neurons from adult rats. After male rats (6–8 weeks old) were decapitated 
under deep anesthesia with 3% isoflurane (Nacalai Tesque), the skin was cut along the dorsal midline. The bone 
was then cut along the midline, and the spinal cord was removed with forceps by sliding them along the cord. The 
meninges were removed to visualize the DRG along the vertebral canal. The DRG were quickly removed one by 
one using forceps and transferred into ice-cold L-15 culture medium (Thermo Fisher Scientific). Next, dissected 
DRG from adult rats were transferred into a tube containing 1 ml of Hank’s balanced salt solution (137 mM NaCl, 
5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 5.6 mM D-glucose, and 2.4 mM 2-[4-(2-hydroxyethyl)-1-pip-
erazinyl]ethanesulfonic acid, adjusted to pH 7.2 with NaOH) supplemented with 0.3% collagenase type II 
(Thermo Fisher Scientific, Inc.) and 0.4% dispase II (Thermo Fisher Scientific, Inc.) and incubated for 1 h at 37 °C 
with gentle shaking approximately every 15 min to ensure equal distribution of the DRG. After incubation, cells 
were mechanically dissociated using a pipette (triturating approximately 50 times). DRG neurons were purified 
by Percoll (Sigma-Aldrich) density gradient centrifugation. Percoll solutions (30% and 70%) were prepared in 
L-15 culture medium. A Percoll gradient was constructed by layering 3 ml of each Percoll solution into a cen-
trifuge tube. Finally, 1 ml of DRG cell suspension was placed on top of the gradient and centrifuged at 1,800 × g 
for 15 min at room temperature. Intermediate fractions between each Percoll solution were collected. After 
washing with L-15 culture medium, cells were re-suspended in Neurobasal medium (Thermo Fisher Scientific) 
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containing 2% B-27 supplement (Thermo Fisher Scientific), 2 mM L-glutamine, 1% penicillin-streptomycin, and 
0.05 μg/ml nerve growth factor 2.5 S (Sigma-Aldrich). Purified DRG neuronal cells were cultured for 10 days on 
PLL/laminin-coated coverslips in Neurobasal medium (Fisherbrand Microscope Cover Glass, Thermo Fisher 
Scientific).
Co-culture of Schwann cells and DRG neurons. Schwann cell/DRG neuron co-cultures were prepared 
as described previously52. Briefly, DRG were dissected from embryonic day 15 Wistar/ST rat pups and plated 
(2 × 105 cells per well) in 24 well plates coated with PLL and laminin and containing Neurobasal medium sup-
plemented with B27 and 100 ng/ml 2.5 S NGF. Non-neuronal cells were removed by treating the cultures with 
medium containing 5-fluorodeoxyuridine (FdUr) (Sigma-Aldrich). Ten days later, the cultures were switched to 
fresh medium without FdUr. Primary Schwann cells were obtained from the sciatic nerves of Wistar/ST rat pups 
(post-natal day 2). Contaminating fibroblasts were removed by treating the cells with 10 μM cytosine arabinoside 
for 48 h and by complement-mediated cytolysis using an anti-Thy1.1 antibody (Serotec) and rabbit complement 
(Cappel). Schwann cells were seeded onto PLL-coated plates and cultured in DMEM supplemented with 10% 
FBS, 2 μM forskolin, and 20 ng/ml rh-HRG-1 (Sigma). After the neural axons grew and expanded, Schwann cells 
(3 × 105 cells per well) were then plated onto established neuronal cultures in DMEM supplemented with 10% 
FBS and 100 ng/ml 2.5 S NGF. Ten days later, the mixed culture of Schwann cells and neurons was treated with 
50 μg/ml ascorbic acid to induce myelination.
Viability of Schwann cells. Immature Schwann cells were seeded in 48 well plates. After reaching 70% 
confluence, cells were differentiated in differentiation medium. After 2 days of culture, cells were exposed to 
cisplatin (0.1–10 μM), oxaliplatin (0.1–10 μM), or paclitaxel (0.001–0.1 μM) for 1 or 2 days. The plated cells were 
then incubated at 37 °C for 45 min in 20 μl of MTT (Nacalai Tesque) solution (final concentration of 0.05 mg/ml). 
The medium was then removed, and the purple formazan crystals were dissolved in 150 μl of DMSO. An aliquot 
of 100 μl was extracted from each well and transferred to 96 well plates. The absorbance was then measured 
in a micro-plate reader (MAXline, Molecular Devices, Sunnyvale, CA, USA) at 560/630 nm. Cell viability was 
expressed as the absorbance value of drug-treated groups × 100/the absorbance value of the vehicle-treated group.
Immunocytochemical analysis of cultured cells. Schwann cells, DRG neurons, and Schwann cell/DRG 
neuron co-cultures were cultured on PLL/laminin-coated coverslips. After differentiation or drug treatment, the 
culture medium was removed and the cells were washed with PBS and fixed with 4% paraformaldehyde in PBS 
for 20 min at room temperature. Cells were washed three times with PBS, blocked, and permeabilized for 30 min 
in 3% BSA in PBS containing 0.1% Tween 20. Consecutively, cells were incubated with mouse anti-CD90/Thy1 
(1:1000, Abcam), rat anti-MBP (1:250, Merck Millipore), mouse anti-p75 (1:500, Merck Millipore), anti-GFAP 
(1:500, Merck Millipore), anti-MAP2 (1:500, Merck Millipore), or rabbit anti-S100 (1:1000, Agilent Technologies, 
Santa Clara, CA, USA) primary antibodies overnight at 4 °C. After washing three times with PBS, cells were incu-
bated for 2 h at room temperature with appropriate secondary antibodies conjugated to Alexa Fluor™ 594 and/
or Alexa Fluor™ 488 (1:200, Thermo Fisher Scientific). After washing, cultures were mounted using Vectashield 
containing DAPI (Vector Laboratories, Burlingame, CA, USA) and images were acquired under a laser scanning 
confocal microscope (Fluoview FV10i Confocal Microscope, Olympus Corporation, Tokyo, Japan). Next, 6–9 
fields (2–3 fields × three independent samples) were selected randomly from each group and the immunore-
active signal intensity was measured using a computer-assisted system (Image J software, National Institute of 
Mental Health, Bethesda, MD, USA). The upper and lower threshold density ranges were adjusted to encom-
pass and match the immunoreactivity to yield an image showing immunoreactive material as white pixels and 
non-immunoreactive material as black pixels. The density of the pixels within the threshold value representing 
immunoreactivity was then calculated. In each case, relative intensity (%) was expressed as the value for the 
drug-treated groups × 100/the value for the vehicle-treated group.
Immunohistochemical analysis of mouse sciatic nerve sections. Male mice received an intraperi-
toneal (i.p.) injection of paclitaxel (4 mg/kg) or saline on Days 0, 3, 5, and 7 as described previously53. On the 
day after the last injection, mice were deeply anesthetized with pentobarbital (50 mg/kg, i.p.; Nacalai Tesque) 
and intra-cardially perfused with freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffer (PB). 
Subsequently, bilateral sciatic nerves were quickly removed. Sciatic nerve sections were post-fixed in 4% par-
aformaldehyde for 4 h and permeated with 15% sucrose solution in 0.1 M PB for 24 h at 4 °C. The sciatic nerve 
sections were then frozen in an embedding compound (Sakura Fintek USA, Torrance, CA, USA) and stored 
at −80 °C until use. Frozen longitudinal segments of sciatic nerve were cut with a freezing cryostat (Leica CM 
1850, Leica Microsystems, Wetzlar, Germany) (16 μm thick) and thaw-mounted on MAS-coated glass slides 
(Matsunami Glass Ind). The sections were then blocked in blocking buffer (PBS containing 0.1% Tween 20 and 
5% normal goat serum, Vector Laboratories) for 1 h at room temperature and then incubated for 24 h at 4 °C 
with the following primary antibodies: mouse anti-p75 (1:500, Abcam) plus rabbit anti-MAP2 (1:250, Merck 
Millipore) or rat anti-GFAP (1:50, Merck Millipore), or rabbit anti-p75 (1:100, Abcam) plus mouse anti-galectin-3 
(1:150, Abcam). The antibodies were rinsed away using PBS (three times) and incubated for 1.5 h at room tem-
perature with appropriate secondary antibodies conjugated to Alexa Fluor™ 488 and/or 594 (1:200, Thermo 
Fisher Scientific). The slides were then cover-slipped with Vectashield. All images were acquired under a laser 
scanning confocal microscope (Fluoview FV10i Confocal Microscope, Olympus Corporation). Nine fields (three 
fields × three independent samples) were selected randomly per group, and the immunoreactive signal intensity 
was measured using a computer-assisted system (Image J). The images were analyzed, and immunoreactivity was 
calculated as described above.
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Western blotting. Schwann cells were homogenized in RIPA-lysing buffer (50 mM Tris-HCl buffer (pH 7.6), 
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, protease inhibitor cocktail (Nacalai Tesque), and 
0.1% sodium dodecyl sulfate (SDS)) using a sonicator (Q55 model, Qsonica, Newtown, CT, USA) and then centri-
fuged at 1000 × g at 4 °C for 10 min. The supernatants were collected, and protein concentrations were determined 
using a BCA Protein Assay Kit (Thermo Fisher Scientific). An aliquot of supernatant was diluted in NuPAGE® 
LDS sample buffer (Thermo Fisher Scientific), and proteins were separated on a 3–12% SDS-polyacrylamide gra-
dient gel. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Merck Millipore), which 
was then blocked for 1 h at room temperature in Blocking One solution (Nacalai Tesque) or blocking buffer com-
prising Tris-buffered saline (TBS) containing 5.0% Difco™ skim milk (Becton, Dickinson and Company, Franklin 
Lakes, NJ, USA) and 0.1% Tween 20. Next, the PVDF membrane was incubated with the following primary 
antibodies in 10% blocking one solution in TBS containing 0.1% Tween 20 (T-TBS) or in blocking buffer over-
night at 4 °C: goat anti-actin (1:2500, Santa Cruz Biotechnology, Dallas, TX, USA), mouse anti-Krox20 (1:500, 
Abnova Corporation, Taipei, Taiwan), rabbit anti-Krox20 (1:200, Santa Cruz Biotechnology), mouse anti-MBP 
(1:1000, Abcam), goat anti-Oct6 (1:2000, Santa Cruz Biotechnology), or rabbit anti-Sox10 (1:1000, Abcam). 
The membrane was washed in T-TBS, followed by a 1 h incubation at room temperature with horseradish per-
oxidase (HRP)-conjugated anti-goat, anti-rabbit, anti-mouse, or anti-chicken IgG (Jackson ImmunoResearch, 
West Grove, PA, USA) antibodies diluted 1:2500 in T-TBS. The PVDF membrane was then washed in T-TBS. 
The antigen-antibody peroxidase complex was detected using enhanced chemiluminescence (Immobilon™, 
Merck Millipore) according to the manufacturer’s instructions, and images were generated using ImageQuant™ 
(LAS500, GE Healthcare Life-Sciences, Uppsala, Sweden). The intensity of each band was determined by Image J 
software and normalized against actin (loading control). Relative density (%) was expressed as the values for the 
drug-treated groups × 100/the value for the vehicle-treated group.
Reverse transcription-polymerase chain reaction (RT-PCR) assay. Total RNA was extracted from 
Schwann cells using the SV Total RNA Isolation system (Promega, Madison, WI, USA), according to the man-
ufacturer’s instructions. Purified total RNA was quantified in a spectrophotometer at 260 nm (NanoDrop 2000; 
Thermo Fisher Scientific). To prepare first strand cDNA, 0.2–1.0 μg of RNA was incubated in 40 μl of buffer 
containing a dNTP mixture, a RT random primer, and reverse transcriptase (High Capacity cDNA Reverse 
Transcription Kit, Thermo Fisher Scientific), according to the manufacturer’s instructions. Each target gene was 
amplified in a 50 μl PCR solution containing 2 mM MgCl2, 0.2 mM dNTP mix, and DNA polymerase (Blend Taq®, 
TOYOBO, Osaka, Japan) along with synthesized primers targeting MBP (sense: 5′-GAA GCC AGG ATT TGG 
CTA CG-3′, antisense: 5′-CAG AGC GGC TGT CTC TTC CT-3′; designed according to GenBank™ sequence 
accession number NM_001025291), Krox20 (sense: 5′-CTA CCC GGT GGA AGA CCT C-3′, antisense: 5′-AAT 
GTT GAT CAT GCC ATC TCC-3′; designed according to GenBank™ sequence accession number U78102.1), 
Sox10 (sense: 5′-TGC TAT CCA GGC TCA CTA CA-3′, antisense: 5′-CAG CTC AGT CAC ATC AAA GG-3′; 
designed according to GenBank™ sequence accession number NM_019193.2), p75 (sense: 5′-GCT GGG TTA 
CCA GCC TGA AC-3′, antisense: 5′-GCA GTG GAC TCG CTG CAT AG-3′; designed according to GenBank™ 
sequence accession number NM_012610), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, sense: 
5′-GTT ACC AGG GCT GCC TTC TC-3′, antisense: 5′-TGA TGA CCA GCT TCC CAT TC-3′; designed accord-
ing to GenBank™ sequence accession number NM_017008). Samples were heated to 94 °C for 2.5 min, 55 °C for 
30 sec, and 72 °C for 1 min and cycled 30 times through 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1 min, with 
a final extension step at 72 °C for 3 min. The mixture was run on 1.5% agarose gels with the indicated markers 
(TOYOBO). The agarose gel was stained with ethidium bromide (Nacalai Tesque) and photographed under UV 
transillumination (PhotoDoc-It™ Imaging System, Analytik Jena AG, Jena, Germany).
Quantitative analysis by real-time PCR. Extraction of total RNA from Schwann cells and preparation 
of cDNA were conducted as described above. cDNA was amplified in 20 μl of a PCR solution containing 10 μl of 
Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific) and primers targeting p75 (sense: 5′-GCT GGG 
TTA CCA GCC TGA AC-3′, antisense: 5′-GCA GTG GAC TCG CTG CAT AG-3′), galectin-3 (sense: 5′-GAC 
ATC GCC TTC CAC TTT AAC C-3′, antisense: 5′-GTC TTT CTT CCC TTC CCC AGT T-3′), and GAPDH 
(sense: 5′-GTT ACC AGG GCT GCC TTC TC-3′, antisense: 5′-TGA TGA CCA GCT TCC CAT TC-3′). PCR was 
performed using the StepOnePlus™ System (Thermo Fisher Scientific) under the following cycling conditions: 
95 °C for 10 min and 60 °C for 1 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Fluorescence 
was detected after each extension step. GAPDH was used as a normalization control, and relative mRNA levels 
were calculated using a comparative Ct method and StepOnePlus™ software (Thermo Fisher Scientific).
Mitochondrial transmembrane potential assay. The mitochondrial transmembrane potential (Δψm) 
of Schwann cells was analyzed using the Δψm-sensitive probe MitoTracker® Red CM-H2XRos (Thermo Fisher 
Scientific) and fluorescence microscopy, according to the manufacturer’s instructions. Briefly, 48 h after treatment 
with anti-cancer agents, the culture medium was removed from cells and replaced with serum-free Advanced 
DMEM/F-12 containing 250 nM MitoTracker® probe. The mixture was then incubated at 37 °C for 30 min. Cells 
were then washed three times with warm serum-free Advanced DMEM/F-12, fixed for 20 min with 4% paraform-
aldehyde, and viewed under a fluorescence microscope (Fluoview FV10i-W Confocal Microscope, Olympus). 
To count immunofluorescent-labeled cells, samples stained with MitoTracker® Red CM-H2XRos were photo-
graphed using FV10i-SW at ×15 magnification. Twelve fields (four fields × three independent samples) were 
selected randomly per group, and immunofluorescent cells were counted. Finally, the total number of positive 
cells per 100 total cells was estimated.
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Statistical analysis. Data were analyzed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) 
and expressed as the mean ± S.E.M. Differences between two groups were compared using Student’s t-test. Data 
from more than two groups were compared using one-way or two-way analyses of variance, followed by the 
Tukey’s multiple comparison test. In all cases, differences of p < 0.05 were considered statistically significant.
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